The SKCCC at Johns Hopkins
Baltimore, Maryland, 21287, United States
Location status: Recruiting
NCT Number: NCT02993900
This research is being done to evaluate multimodality imaging, including magnetic resonance imaging-guided therapy (MRT), as a possible treatment for gynecologic cancers. The therapy takes place in the Department of Radiation Oncology at the Johns Hopkins SKCCC. The purpose of this study is to investigate the ability of MRI to successfully guide the placement of the brachytherapy applicator necessary to treat participants' gynecologic cancer. The Investigators want to see if the use of MRI will do a better job of assessing the tumor at the time of brachytherapy than the routinely used CT scan. The Investigators also want to determine if the use of MRI will enable doctors to reduce the radiation dose received by the body during the process of treating the tumor.
Interested in participating?
Request Info18 year–100 year
Female
Interventional
Not applicable
Baltimore, Maryland, 21287, United States
Location status: Recruiting
The goal of this trial is to assess how magnetic resonance imaging (MRI) may be used to improve tumor and normal tissue volume delineation, reducing toxicity and recurrence in gynecologic brachytherapy. The Investigators will compare dosimetric values to the organs at risk (OAR) with CT versus MRI planning. The Investigators anticipate that MR-planned cases will have lower OAR doses than standard CT-based cases due to more conformal planning. The Investigators will determine dose thresholds for radiation-related toxicity after treatment. The Investigators will compare toxicity rates at 6 months, 1 and 2 years after treatment, thereby enabling improved recommendations on dose limits to the OAR.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Brachytherapy will be precisely inserted with the assistance of magnetic resonance (MRI) scans
Time frame: 3 years
To quantify the relative reduction of dose to rectum, sigmoid and bladder obtained after MR Simulator Suite-guided placement, as compared to standard CT guided treatment based on historical information and literature review.
Time frame: 3 months, 6 months and 1 year
To determine the rate of treatment-related toxicity within 3 months, 6 months and 1 year after MR Simulator Suite-guided placement.
Time frame: 1 year and 2 year
To determine the local failure rates at 1 year and 2 year after MR Simulator Suite-guided placement.
Time frame: 1 year and 2 year
To determine the overall survival rates at 1 year and 2 year after MR Simulator Suite-guided placement.
Contact information is provided by the study sponsor or research team.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
A Clinical Trial To Evaluate Image-Guided Gynecologic Brachytherapy In The MR Simulator Suite
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04028479
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Idaho Falls, Idaho, United States
View Trial DetailsNCT06582849
Adnexal Diseases, Anal Cancer
St Louis, Missouri, United States
View Trial DetailsNCT07124000
Adenocarcinoma, Adenocarcinoma (NOS)
Birmingham, Alabama, United States
View Trial DetailsNCT05743517
Adnexal Diseases, Behavior
Chicago, Illinois, United States
View Trial Details